On October 29, Hailir released the third quarter report of 2022, and the company achieved an operating income of 3.803 billion yuan in the first three quarters, a year-on-year increase of 47.2%; The net profit attributable to shareholders of the listed company was 431 million yuan, a year-on-year increase of 38.41%; Basic EPS was 1.26 yuan, up 36.96% year on year. Weighted return on equity is 13.89%.

In recent years, the company has continued to diversify its product layout and expand its own scale. Following the Hengning Phase I project, the company plans the Qingdao Hengning Biotechnology Co., Ltd. Phase II project, and announced in April 2022 that it plans to invest 301 million yuan to build a "new fungicide, herbicide technical drugs and technical drug intermediates construction project", involving 3000 tons/year of propionazole technical drugs and other technical drug products and by-products, In the future, with the gradual progress of relevant projects, the company's product layout is expected to be further improved. At the same time, the company continued to extend its industrial chain. In June 2022, the company announced that it planned to purchase 26% of the equity of Shanxi Jinxinyi. One of the main target products was one of the important intermediates of the company's fungicide product, albendazole. In the future, the stability of the company's core supply chain was expected to be improved, and the strategic layout of intermediates and drugs was expected to be strengthened, contributing to the improvement of the company's profitability.

With the arrival of winter heating season, the whole industry and the company have ushered in the critical moment of "winter storage and winter attack". In the fourth quarter, all factories and all departments of the Group will continue to strengthen operation and management, pay attention to safety and environmental protection, improve the overall quality of operation and management, actively organize effective production, and fully ensure market supply. We firmly believe that the company's performance will still be well reflected this year.